May 22, 2012

CLOSE

To subscribe to updates from this journal click Confirm. Updates will be displayed in your default RSS reader.

Produced and published by Remedica Medical Education and Publishing Limited.

» Contact us

CML Breast Cancer

» Advanced search

Paper of the Month - Volume 22 Issue 1

Please login to access this article in full. Click here to register for free now!

Registered users login here:

Email Address:
Password:

If you have forgotten your password click here


1 ratings / 4 average

Bevacizumab in the Treatment of Metastatic Breast Cancer

Shari B Goldfarb, MD, Maura N Dickler, MD, and Tiffany A Traina, MD

Proangiogenic factors such as vascular endothelial growth factor (VEGF) regulate tumor angiogenesis, which is necessary for breast cancer development, invasion, growth, and metastasis [1–6]. In addition to being one of the central growth factors responsible for neovascularization, VEGF has prognostic significance. Higher levels of VEGF expression are associated with poor clinical outcomes and reduced disease-free survival (DFS) and overall survival (OS) rates in patients with breast cancer [5–8]. Therefore, VEGF is an appropriate target for the pharmacological inhibition of angiogenesis [9–11].

Please login or register to continue reading this article

READER POLL

What approach do you currently use for the treatment of patients with HER2-overexpressing metastatic breast cancer whose disease has progressed despite trastuzumab?

Continuation of trastuzumab with an alternative cytotoxic agent
An alternative cytotoxic agent alone
A HER1/2 tyrosine kinase inhibitor with or without cytotoxic chemotherapy
Continuation of trastuzumab with a HER1/2 tyrosine inhibitor
Other

Find us on
Facebook

Post Page On

SUBMIT AN ARTICLE

» Click here

© Remedica 2012. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without the prior permission of the copyright owners. While every effort is made by the publishers and editorial board to see that no inaccurate or misleading data, opinions, or statements appear in this journal, they wish to make it clear that the material contained in the publication represents a summary of the independent evaluations and opinions of the authors and contributors. As a consequence, the board, publishers, and any supporting company accept no responsibility for the consequences of any such inaccurate or misleading data or statements. Neither do they endorse the content of the publication or the use of any drug or device in a way that lies outside its current licensed application in any territory. For detailed information on any drugs or devices discussed in this publication, readers are advised to consult the manufacturer’s prescribing information.

Produced and published by Remedica Medical Education and Publishing Limited.

May 22, 2012 CLOSE To subscribe to updates from this journal click Confirm. Updates will be displayed in your default RSS reader. Produced and published by Remedica Medical Education and Publishing Limited. » Contact us

CML Breast Cancer » Advanced search